Home DNA Damage/DNA Repair Topoisomerase inhibitor 9-amino-CPT (9-Aminocamptothecin)

research use only

9-amino-CPT (9-Aminocamptothecin) Topoisomerase inhibitor

Cat.No.S2653

9-Aminocamptothecin (9-amino-CPT, 9-AC, Aminocamptothecin, 9-amino-20(S)-camptothecin) is a Topoisomerase I inhibitor with potent anticancer activities. It is an active, water-insoluble derivative of camptothecin.
9-amino-CPT (9-Aminocamptothecin) Topoisomerase inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 363.37

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: S265301 4-Methylpyridine]10 mg/mL]true]DMSO]0.78 mg/mL]false]Water]Insoluble]false Purity: 99.17%
99.17

Chemical Information, Storage & Stability

Molecular Weight 363.37 Formula
C20H17N3O4
 Storage (From the date of receipt) 3 years -20°C powder
CAS No. 91421-43-1 -- Storage of Stock Solutions

Synonyms 9-AC, Aminocamptothecin, 9-amino-20(S)-camptothecin Smiles CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC=C5N=C4C3=C2)N)O

Solubility

In vitro
Batch:

4-Methylpyridine : 10 mg/mL

DMSO : 0.78 mg/mL (2.14 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
Topo I [1]
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04909489 Unknown status
Traditional Chinese Medicine|Dyslipidemias|Syndrome
Dongzhimen Hospital Beijing
 April 21 2021 --
NCT03978624 Active not recruiting
Bladder Cancer
UNC Lineberger Comprehensive Cancer Center|Merck Sharp & Dohme LLC|Syndax Pharmaceuticals
 September 23 2020 Phase 2
NCT00003154 Completed
Lung Cancer
Case Comprehensive Cancer Center|National Cancer Institute (NCI)
 January 1998 Phase 2
NCT00002745 Completed
Lymphoma
National Cancer Institute (NCI)
 April 1996 Phase 2
NCT00251368 Completed
Leukemia Myelocytic Acute|Acute Lymphocytic Leukemia
Dana-Farber Cancer Institute|Brigham and Women''s Hospital|Beth Israel Deaconess Medical Center|Massachusetts General Hospital
 January 1995 Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Signaling Pathway Map